American Society of Clinical Oncology

graphic image of a cube with an arrow nailing the bullseye
Biotech

ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC

The companies plan to submit the EGFR tyrosine kinase inhibitor for an FDA approval during the second half of this year.
Gabrielle Masson May 22, 2025 5:00pm
equity inclusion

ASCO, ACCC issue clinical trial diversity recommendations

May 20, 2022 10:33am